What is the efficacy of rechallenging with ribociclib and letrozole in patients with hormone receptor-negative breast neoplasms?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18760033
Cited by: 0

Abstract

No evidence supports the efficacy of rechallenging with ribociclib and letrozole in hormone receptor-negative breast cancer, as these therapies target hormone pathways relevant to HR+ cancers.

Fields of Study & Subjects

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies PARP inhibition in cancer therapy

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
24 February 2026
Language
EN